We have developed an indirect sandwich ELISA for measuring plasma apolipoprotein E (apo-E), using commercially available antibodies. A monoclonal anti-apo-E was used as the capture antibody and the captured apo-E detected with polyclonal anti-apo-E antiserum (goat). The detecting antibody was quantitated using horseradish peroxidase-conjugated rabbit immunoglobulin to goat immunoglobulins. There was no detectable cross-reactivity between the three antisera. Interference with the assay by apolipoprotein A-I, bilirubin and haemoglobin was not significant up to 1·7 giL, 1250 umol/L and 13·0 g/dL, respectively. The ELISA method showed high correlation with an established immunonephelometric method (ELISA apo-E= 1·04 Immunonephelometric apo-E+ 16; r 2=0'954, P<O·OOOl, n = 39). The assay has a measuring range between 5 and 560 mg/L, The coefficient of duplicates was 2'0%, within-run coefficients of variation (CV) ranged from 3·7 to 6·0% and between-run CV from 6·1 to 15-1 %. The reference range determined for 168 normotriglyceridaemic subjects was 20 to 130 mg/L, In an analysis of the lipoprotein subfractions isolated by ultracentrifugation as the fraction of density less than 1·25 g/ml, and separated by gel permeation chromatography, apo-E was found to be associated with very low-density lipoprotein and large high-density lipoprotein.
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Apolipoprotein E (Apo-E) is one of the protein constituents of plasma lipoproteins that serve various functions, including maintenance of the structure of the lipoprotein particles and regulation of the metabolism of several different lipoproteins.I) Apo-E is a glycoprotein of 299 amino acids with a molecular weight of about 34000 Da, and is a constituent of normal human chylomicrons, very low-density lipoproteins (VLDL) and a subclass of high-density lipoproteins (HDL).l A major role for apo-E in lipoprotein metabolism is its ability to mediate high-affinity binding of apo-E-containing lipoproteins to the low density lipoprotein receptor, also referred to as the apo-B,E receptor;' to Correspondence: Dr R Bais, Department of Biochemistry, Royal North Shore Hospital, St Leonards, NSW, Australia 2065. initiate the cellular uptake and degradation of the lipoproteins. Apo-E also mediates the binding of chylomicron remnants to a second, postulated, hepatic receptor, the so-called chylomicron remnant receptor.l-" Apo-E is also involved in reverse cholesterol transport, the mechanism by which it is postulated that cholesterol can be transported from the peripheral tissues to the liver.' It is proposed that cholesterol is transported by HDL particles and that as the HDL particles become cholesterol enriched, they also acquire apo-E, available in the interstitial fluid as a product secreted by various cells.I, 6 These particles can then be cleared via the apo-B,E receptor. In addition to its role in lipoprotein metabolism, apo-E is involved in immunoregulation. The apo-E containing lipoproteins have the ability to inhibit or stimulate antigen-and mitogen-induced T lymphocyte activation and proliferation. 6 ,7 Apo-E plays a central role is dysbetalipoproteinaemia (familial type III hyperlipidaemia), a genetically determined disease which occurs in about 1 in 5000 Caucasians. Abnormally synthesized apo-E fails to interact with the apo-B,E and apo-E receptors in the liver which results in impaired lipid clearance and high concentrations of plasma apo-E. Untreated, the condition is associated with an extremely high incidence of coronary and peripheral vascular disease,"
A simple and reliable method for measuring plasma apo-E concentration would not only be useful for strengthening the diagnosis of dysbetalipoproteinaemia but would also be a valuable research tool to use in understanding the role of apo-E in lipid metabolism. Plasma apo-E concentrations have been measured by a number of different methods including radial immunodiffusion.? radioimrnunoassay.l'' immunoturbidimetry, I 1 immunonephelometryl-and ELISA. 13, 14 Methods such as immunoturbidimetry and immunonephelometry use relatively high concentrations of antibody which make them expensive, especially for small batched or infrequent assays. Radioimmunoassays are time-consuming, have the disadvantage of involving radioactive material and the reagents have limited stability. The other disadvantage of all apo-E assays described so far is that they either use antibodies prepared in specialized laboratories which are not readily available, or are dedicated to a particular instrument. We have developed and characterized an indirect sandwich ELISA method for measuring plasma apo-E using commercially available antibodies. We have used this assay to determine the reference interval for apo-E. BSA is PBS containing 5 gIL BSA and PBS/T is PBS containing 5 gIL Tween-20. TBS buffer was composed of 10 mmol/L Tris-HCI, pH 7·4 containing 0·15 mol/L NaCl, 0·13 mmol/L EDTA and 0,9 mrnol/L sodium azide. The horseradish peroxidase substrate was composed of 50 mmol/L Na 2HP04, 25 mmol/L citric acid, 2·2 mmol/L O-phenylenediamine and 10 mmol/ L H 202 (final pH = 5'0).
MATERIALS AND METHODS

Antibodies
The initial work on this assay was carried out using mouse monoclonal anti-human apo-E antiserum, 6H7 (Clinical Research Institute of Montreal, Quebec, Canada) as the capture antibody to coat the plastic solid phase. However, in subsequent studies we have used a mouse monoclonal anti-human apo-E, 21-F3-D2 which was obtained from Biogenesis Ltd (Bournemouth, UK). There was no difference in the results obtained with either of these monoclonal antibodies. Goat polyclonal antihuman apo-E antiserum (Daiichi Pure Chemical Co Ltd, Japan, Lot No. 015SDM) was used as the detecting antibody to quantitate the amount of apo-E antigen bound to the solid phase capture antibody. Horseradish peroxidase conjugated rabbit immunoglobulin to goat immunoglobulin (Dakopatts, Denmark) was used to quantitate the detecting antibody on the solid phase.
Apo-E calibrator and control sera The calibrator was a lyophilized preparation of reference standard human apo-E (Lot No. 006SBM, Daiichi Pure Chemical Co Ltd). This calibrator had an ascribed apo-E value of 28 mg/L, Control plasma with a low apo-E value was prepared by pooling the plasma from four normolipidaemic subjects (triglycerides < 2·0 mmoljL and total cholesterol < 4·5 rnmol/ L) and for the high level control plasma, plasma from four hyperlipidaemic subjects (triglycerides > 2·0 mmol/L and cholesterol > 7·0 mmol/L) was pooled. The high and low controls were diluted 1:2000 in PBSjBSAjT, aliquoted and stored at -70°C.
Samples
For the determination of the reference interval, blood was collected into tubes containing EDTA from staff of the Institute of Medical and Veterinary Science after an overnight fast. Plasma was separated by centrifugation and stored at -70°C. For the patient studies described, plasma was selected from routine fasted samples submitted to the Lipid Unit of the Division of Clinical Biochemistry. These samples were divided into three groups according to their lipid composition. One patient in the hypertriglyceridaemic group was subsequently diagnosed as having dysbetalipoproteinaemia,
Apo-E ELISA procedure An apo-E calibrator stock solution was prepared by diluting the apo-E calibrator in PBS/BSA/T to 392 ngjml., This apo-E calibrator solution was then serially diluted to cover a range from 24·5 to 392 ng/ml., Once prepared and aliquoted, these diluted samples were stored at -70°C for 1 year without any apparent loss of activity. Plasma samples were freshly diluted 1:2000 in PBS/BSA/T.
To coat the microtitre wells with antibody, the antibody obtained from the Clinical Research Institute of Montreal was diluted 1:500 with PBS and 100 ul, added to each well. For the antibody obtained from Biogenesis, 200 ul, of PBS was added to the vial and then 100 ul, of a 1:3000 dilution added to each well. The plate was then incubated overnight with gentle shaking, after which unbound antibody was decanted and 150 ul, of PBS/BSA added to each well to block the non-specific binding sites on the solid phase. The plate was shaken on a Mixx 1 microtitre plate shaker (Bioclone Aust Pty Ltd, Sydney, Australia) for 1 h. The plate was then washed four times with PBS/T using a Denley Microplate Washer (Bioclone Aust Pty Ltd, Sydney, Australia). One hundred microlitres of calibrator, control serum or sample was then added, in duplicate, to the appropriate wells and incubated with shaking for 2 h. At the end of the incubation, the plate was washed four times with PBS/T and 100 ul, of goat polyclonal antihuman apo-E antiserum (diluted 1:1000 with PBS/ BSAfT) added to each well. The plate was incubated for a further 2 h and then washed four times with PBSfT. The horseradish peroxidase conjugated rabbit anti-goat antiserum was diluted 1:1000 in PBS/BSAfT and 100 ilL added to each well. After a 2 h incubation the plate was washed four times with PBS/To Quantitation was determined by adding 100 ul, of freshly prepared O-phenylenediamine substrate. The colour reaction was allowed to proceed for exactly 5 min in the dark and stopped by the addition of 100 ul, of I mol/L sulphuric acid. The absorbance was read within 10 min at Apo-E ELISA 121 490 nm using a V Max Kinetic Microplate Reader (Bioclone Aust Pty Ltd, Sydney, Australia). All these solutions were prepared immediately prior to use. Apo-E immunonephelometry was performed with a Beckman Array Protein Assay System (Beckman Instruments (Aust) Pty Ltd, Sydney, Australia) using the protocol supplied by the manufacturer.
Chromatography of lipoprotein fractions
Blood was collected into tubes containing EDTA from subjects who had fasted overnight and the plasma isolated by centrifugation. The density of the plasma was adjusted to 1·25 gjrnl, with solid KBr and ultracentrifuged at 100000 rpm for 16 h in a Beckman TL-IOoo Ultracentrifuge using a TLA 100.2 rotor. The lipoprotein fraction (d< 1·25 g/mL) was collected by tube slicing and 200 ilL loaded onto a Superose 6HR 10/30 FPLC column (Pharmacia, Sweden) which had been equilibrated with TBS buffer. Fractions of O' 5 mL were collected.
Statistical calculations
The microtitre plate reader was connected to a Pharmacia Multicalc Immunoassay Data Management Program. Standard curves were constructed using a four-parameter spline fitting algorithm. The apo-E concentrations were then calculated using the equation fitted to the standard curve.
Data were analysed using a JMP statistical software package (SAS Institute, Inc). All results are expressed as mean (SD). The relationship between ELISA and immunonephelometric apo-E measurements was assessed by least squares linear regression analysis. Reference intervals were determined using the computer program REFVAL.15
RESULTS
Cross-reactivity and interference
The cross-reactivity among the different antibodies was evaluated by successively omitting the antigen and each of the antibodies in the ELISA procedure. The absorbance of the final colour development was indistinguishable from the background absorbance indicating there was no detectable cross-reaction betweene these antibodies.
The interference of the ELISA procedure by apolipoprotein A-I, bilirubin and haemoglobin was tested by adding increasing amounts of each to a plasma sample of known apo-E concentra- 
Reference interval
The reference interval of plasma apo-E concentration was determined on fasted plasma from 168 apparently normal volunteers from the staff of the IMVS using REFVAL. All were normotriglyceridaemic (triglyceride < 2·0 mmo1jL). The REFVAL program initially carries out a Guassian fit to the data and if this is not statistically valid, a non-parametric fit is performed. The apo-E reference interval was obtained from the non-parametric fit of the data. The results (Fig. 2) gave a reference interval of 20 to 130 mgjL. There was no difference between males and females.
Precision profile
The variation between duplicate assays of 20 different samples, expressed as a CV, was 2%. The within-assay CV was estimated by measuring five different plasma samples at 14 replicates on the same plate and found to be between 3·7 and 6·0% (Table 1 ). The between-assay CV was estimated by measuring the same five plasma samples at 14 replicates on six different occasions (64 assays for each sample) and found to be between 6·1% and 15·1% ( Table 2) . each were serially diluted from 1:100 to 1:12 800 in PBSjBSA/T. The dilution curve of the plasma sample was parallel to the calibrator in the range 1:100 to 1:3200 ( Fig. 1) indicating that, within this range, both behave similarly in the assay system.
The lowest limit of the assay was determined as the apo-E concentration at which the calibration curve was virtually fiat. This limit corresponded to a dilution between 1:3200 and 1:6400 of the calibrator and was equivalent to less than 2·5 mg/L. Since all samples are diluted 1:2000, the measuring range for plasma was thus between 5 and 560 mgjL.
Apo-E (mglL) Comparison with immunonephelometry The apo-E ELISA method was compared to the Beckman apo-E imrnunonephelometric assay. Both assays were performed on the same day. There was good agreement between the apo-E concentration measured by the two assay systems which was represented mathematically as ELISA apo-E= 1·04 imrnunonephelometry + 16 (r2=0'954, P<O'OOOI, n=39) .
Relationship between apo-E concentration and lipid levels
The subjects used in the comparison studies were divided into normolipidaemic, hypertriglyceridaemic and hyperlipidaemic groups according to their lipid profiles ( Table 3 ). The hypertriglyceridaemic subjects had significantly higher mean plasma apo-E levels than the normolipidaemic subjects ( P < 0.05) but there was no significant difference between the normolipidaemic and hypercholesterolaemic subjects. The dysbetalipidaemic patient had an apo-E level of 357 mgjL.
Apo-E ELISA 123
Distribution of apo-E in different lipoprotein subfractions The distribution of apo-E in different lipoprotein subfractions of three normal subjects and a chronic alcoholic is shown in Fig. 3 . In all subjects, there were two major apo-E peaks, one which coincided with the elution position of VLDL and the other with the beginning of the HDL-cholesterol peak. In all subjects there was a low and variable level of apo-E in the lowdensity lipoprotein (LDL) region. Subject JR was a chronic alcoholic and although this profile showed a much greater HDL-cholesterol level, the apo-E profile was not significantly different from the normal subjects.
DISCUSSION
Although the immunonephrolemetry assay used as the comparison method in this study was a more rapid method for measuring plasma apo-E concentrations (30 min compared with 7-8 h), this method requires specialized equipment and reagents. We have estimated the cost of our ELISA method to be less than one-fifth the cost of the Beckman Array apo-E assay. With the ELISA method, there are relatively long incubation steps but the actual time for someone to perform the assay, is about one hour spread over the day. In addition, because of the stability of the reagents, the convenience in doing the assays and the relative cost, the ELISA method is ideal for small batches, or infrequent assays. The antigenic determinant of some apolipoproteins is concealed within the lipid phase of the lipoprotein and may not be accessible to the antibody. Thus, the non-ionic detergent, Tween-20, was added to the sample dilution buffer." The addition of BSA to the diluent was necessary to stabilize the apo-E by acting as an apo-E carrier protein." The assay uses a monoclonal antibody as the capture antibody. Monoclonal antibodies react with a single epitope on the antigen and it could be questioned whether the antibody is capable of binding equally all apo-E forms present in plasma. We believe this to be so as comparable results were obtained with the two monoclonal antibodies used in the study and with the Beckman Array system which uses a polyclonal antibody. Imprecision of the assay increased at higher apo-E concentrations which is acceptable clinically and, because of the large difference in apo-E concentration, would not prevent differentiating normals from patients with lipid disorders such as dysbetalipoproteinaemia.
One of the problems with many apolipoprotein assays including apo-E is the lack of an acceptable calibrator. This issue has been highlighted for apolipoproteins A-I and B for which acceptable, well-characterized calibrators have only recently become available. 17 ,18 The apo-E calibrator used in this study is commercial material which had an assigned value of 28 mg/ L and the calibrator used in the Beckman immunonephelometric assay has a value assigned by the manufacturer. The reason for the significant bias of 16 mg/L between the two assays is not clear. It may be due to differences in the assigned value of the calibrator used in these assays or more likely to the differences between the methods of calibration for the assays. The ELISA uses serial dilutions of the calibrator whereas the Array uses a single point calibration.
There are large discrepancies in the reported normal plasma apo-E concentrations with the mean apo-E concentration ranging from as low as 36 mg/L to as high as 246 mg/L. [9] [10] [11] [12] [13] 19 The reason for such large variations is not well understood but could be due to the selection of a sample population which may have included hypertriglyceridaemic subjects or the use of different antisera and apo-E standards in different methods. 13 In addition, wide variations in imrnunoassays can also be due to the use of either monoclonal or polyclonal antibodies and the species from which these are obtained.P
The high concentration of plasma apo-E in the hypertriglyceridaemic patients was predictable and has been reported previously.IO. 21 Apo-E is a major constituent of both chylomicrons and VLDL which contain high concentrations of triglycerides and the high concentration merely reflects this association. The dysbetalipoproteinaemia patient had an apo-E concentration of 357 mg/L, The reported concentrations for such patients range from 240 to 800 mg/L.9.12,13,20 However, it must be emphasized that such high concentrations of apo-E alone are not sufficient to diagnosis dysbetalipoproteinaemia and that a combination of clinical signs (palmer and tuberous xanthoma), family history, the results from lipid analysis, lipoprotein electrophoresis or apo-E genotyping are required before the diagnosis can be confirmed. 22 This assay has also been shown to be suitable for research purposes in the analyses of samples after lipoprotein chromtography. It was shown that the first peak of apo-E immunoreactivity coincided with the elution volume of VLDL and that a second peak which was variable in size eluted between VLDL and HDL. A third peak overlapped with the ascending limb of the peak of HDL, which indicates that these lipoproteins containing apo-E have a greater Stokes radius than typical HDL suggesting that the subclass of HDL particles containing apo-E are larger and less dense than HDL 2 . 10 As described earlier, as HDL becomes cholesterol enriched, they acquire apo-E and can interact with the apo-B,E receptor which is postulated to be the mechanism of so-called reverse cholesterol transport. I The significance of apo-E levels is not well understood especially the association with various lipoprotein subfractions. It should be noted that ultracentrifugation of plasma can deplete lipoproteins of apo-E and the absolute concentrations could be affected by this procedure but, these data do show that the assay can be used for determining apo-E distribution in various lipoprotein particles.
